Skip to main content Accessibility help
  • Print publication year: 2012
  • Online publication date: May 2012

45 - Weakness

from Section 2 - Primary Complaints


1. AdamsHP, BrottTG, CrowellRM, et al. Guidelines for the management of patients with acute ischemic stroke: A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Stroke 1994;25:1901–14.
2. AdamsHP, BrottT, FurlanAJ, et al. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke: A statement for health care professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation 1996;94:1167–74.
3. AdamsHP, DavisPH, LeiraEC, et al. Baseline NIH Stroke Scale strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999;53:126–31.
4. AlbersGW, AmarencoP, EastonJD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001;119:300S–20S.
5. AlbersGW, BatesVE, ClarkWM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283:1145–50.
6. AminA. Parenteral medication for hypertension with symptoms. Ann Emerg Med 2008;51(3):S10–15.
7. AsimosAW. Weakness: A systematic approach to acute, non-traumatic, neurologic and neuromuscular causes. Emerg Med Pract 2002;4(12).
8. BroderickJ. Endovascular therapy for acute ischemic stroke. Stroke. 2009;40:S103–6.
9. BrottT, BogousslavskyJ. Treatment of acute ischemic stroke. N Engl J Med 2000;343:710–22.
10. CulebrasA, KaseCS, MasdeuJC, et al. Practice guidelines for the use of imaging in transient ischemic attacks and acute stroke: a report of the stroke council, American Heart Association. Stroke 1997;28:1480–97.
11. DalakasMC, HohlfeldR. Polymyositis and dermatomyositis. Lancet 2003;362:971–82.
12. DalakasMC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004;291:2367–75.
13. EdlowJA, McGillicuddyDC. Tick paralysis. Infect Dis Clin North Am 2008;22:397–413.
14. FurlanA, HigashidaR, WechslerL, et al. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study: A randomized controlled trial. JAMA 1999;282:2003–11.
15. GrottaJ. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? t-PA the best current option for most patients. N Engl J Med 1997;337:1310–13.
16. HackeW, KasteM, BluhmkiE, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke (ECASS III). N Engl J Med 2008;359:1317–29.
17. HughesRAC, CornblathDR. Guillain Barré syndrome. Lancet 2005;366:1653–66.
18. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): A randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet 1997;349:1569–81.
19. JauchEC, KisselaB, StettlerB. Acute stroke management. Updated September 28, 2010. Available at: (accessed February 10, 2011).
20. JohnstonSC, GressDR, BrownerWS. Short-term prognosis after emergency department diagnosis of transient ischemic attack. JAMA 2000;284(22):2901–6.
21. KhatriP, YeattsSD, BroderickJ, TomsickT, for the IMS I and II Investigators. Good outcome after technically successful intra-arterial therapy is time-dependent. Stroke. 2008;39:560. Abstract.
22. LatovN. Use of intravenous gamma globulin in neuroimmune disease. J Allergy Clin Immunol 2001;108(suppl. 4): S126–32.
23. LehmannHC, HartungHP, HetzelGR, et al. Plasma Exchange in Neuroimmunological Disorders, Part 1: Rationale and Treatment of Inflammatory central Nervous System Disorders. Arch Neurol 2006;63:930–5.
24. LehmannHC, HartungHP, HetzelGR, et al. Plasma exchange in neuroimmunological disorders, part 2: Treatment of neuromuscular disorders. Arch Neurol 2006;63:1066–71.
25. MarlerJR, Winter-JonesP, EmrM (eds). Proceedings of the National Symposium on Rapid Identification and Treatment of Acute Stroke. The National Institute of Neurological Disorders and Stroke. NIH Publication No. 97–4239, National Institutes of Health, Bethesda, MD, 1997, pp. 157–8.
26. McGillicuddyDC, WalkerO, ShapiroNI, et al. Guillain-Barré syndrome in the emergency department. Ann Emerg Med 2006;47(4):390–3.
27. MeriggioliMN, SandersDB. Autoimmune myasthenia gravis: Emerging clinical and biological heterogeneity. Lancet Neurol 2009;8:475–90.
28. MitkaM. Lifestyle changes key to cut stroke risk: Guidelines place emergency physicians on the front line. JAMA 2011;305(6):551–2.
29. NovakJC, Lovette-RacheAE, RackeMK. Monoclonal antibody therapies and neurological disorders. Arch Neurol 2008;65(9):1162–5.
30. SmithWS, SungG, StarkmanS, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: Results of the MERCI Trial. Stroke 2005;36:1432–8.
31. SmithWS, SungG, SaverJ, et al, Multi MERCI Investigators. Mechanical Thrombectomy for Acute Ischemic Stroke: Final Results of the Multi MERCI Trial. Stroke 2008;39:1205–12.
32. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–7.
33. ThompsonJD, FillouxFM, Van OrmanCB, et al. Infant botulism in the age of botulism immune globulin. Neurology 2005;64:2029–32.
34. ThurmanRJ, JauchEC. Acute ischemic stroke: Emergent evaluation and management. Emerg Med Clin North Am 2002;20:609–30.
35. WangEE, MahajanN, WillsB, et al. Successful treatment of potentially fatal heavy metal poisonings. J Emerg Med 2007;32(3):289–94.
36. WinerJB. Guillain-Barré syndrome. BMJ 2008;337:a671.
37. von DoornPA, RutsL, JacobsBC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7:939–50.